Philips Beats Estimates, Takes Respironics Charge
Koninklijke Philips posted third-quarter adjusted earnings above forecasts while booking a 288-million-euro provision tied to a U.S. Justice Department settlement.
Updated on Nov. 3, 2026 in Healthcare
Koninklijke Philips reported third-quarter adjusted earnings of 46 cents, above a consensus estimate of 37 cents, on sales of $5.06 billion. Income from operations fell 50% to 165 million euros, largely because of a 288-million-euro provision for the Respironics settlement with the U.S. Department of Justice.
Why it matters
The settlement charge drove a sharp drop in reported operating income even as underlying operations improved, offering readers of the healthcare sector a view of how legacy litigation can weigh on results. The company's adjusted figures and reiterated outlook give investors a clearer picture of core performance.
Comparable sales rose 3% and adjusted EBITA reached 569 million euros, a 13.0% margin, while Diagnosis & Treatment sales hit 2.09 billion euros. The 200-million-euro U.S. tariff refund lifted the free cash flow outlook, though the filing does not address the broader effect of cost inflation beyond the EBITA bridge.
The players
Koninklijke Philips
A Dutch multinational healthcare technology company known for medical imaging, diagnostic and patient monitoring equipment.
U.S. Department of Justice
The federal U.S. agency that negotiated the Respironics settlement with Philips over the sleep and respiratory device recall.
The details
Higher sales, a stronger gross margin and productivity measures lifted adjusted EBITA, partly offset by cost inflation. Mid-single-digit growth in Image Guided Therapy was offset by a mid-single-digit decline in Precision Diagnosis.
Timeline
Payment of the Respironics settlement is expected in the first quarter of 2027.
Capital markets targets run from 2026 to 2028, including mid-single-digit comparable sales growth.
The company targets a mid-teen adjusted EBITDA margin by 2028.
Market Landscape
The 288-million-euro Respironics provision continues the financial fallout from the device recall that has weighed on Philips since the U.S. Justice Department litigation began. Philips' results show that operational gains in imaging and diagnostics are now being measured against those legacy liabilities.
For customers and patients who rely on Philips respiratory and imaging equipment, the settlement does not change current product availability or pricing as reported. The results indicate the company is prioritizing margin and productivity gains, which matters for hospital buyers evaluating long-term equipment contracts.
The takeaway
Philips' results show that a large legal settlement can overshadow strong operating performance in a single quarter. Readers tracking healthcare companies should look at adjusted figures alongside reported operating income to understand the underlying business.
What happens next
Philips expects to pay the Respironics settlement in the first quarter of 2027, and its 2026 comparable sales growth outlook of 3% to 4.5% and adjusted EBITA margin outlook of 13.5% to 14% will be tested against results in the coming quarters.
Further reading
Explore more Healthcare coverage for context on how medical device makers are managing regulatory settlements.
Source note: This article includes information reported by Benzinga.
